Determination of Taxotere in human plasma by a semi-automated high-performance liquid chromatographic method

doi:10.1016/0378-4347(92)80333-L

Journal of Chromatography B: Biomedical Sciences and Applications

Volume 582, Issues 1–2, 6 November 1992, Pages 273-278

https://doi.org/10.1016/0378-4347(92)80333-L Get rights and content

Abstract

A rapid, selective and reproducible high-performance liquid chromatographic (HPLC) method with ultraviolet detection was developed for the determination of the anti-cancer agent Taxotere in biological fluids. The method involves a solid-phase extraction step (C₂ ethyl microcolumns) using a Varian Advanced Automated Sample Processor (AASP) followed by reversed-phase HPLC. The validated quantitation range of the method is 10–2500 ng/ml in plasma with coefficients of variation ≤ 11%. The method is also suitable for the determination of Taxotere in urine samples under the same conditions. The method was applied in a phase I tolerance study of Taxotere in cancer patients, allowing the pharmacokinetic profile of Taxotere to be established.

References (8)

J. Rizzo et al.
J. Pharm. Biomed. Anal.
(1990)
W.J. Slichenmyer et al.
J. Clin. Pharmacol.
(1990)
F. Gueritte-Voegelein et al.
J. Med. Chem.
(1991)
M.-C. Bissery et al.
Cancer Res.
(1991)

There are more references available in the full text version of this article.

Cited by (108)

Implication of linker length on cell cytotoxicity, pharmacokinetic and toxicity profile of gemcitabine-docetaxel combinatorial dual drug conjugate
2018, International Journal of Pharmaceutics
The present study investigates effect of linkers [zero length (without linker), short length linker (glycine and lysine) and long length linker (PEG1000, PEG2000 and PEG3500)] on pharmacokinetics and toxicity of docetaxel (DTX) and gemcitabine (GEM) bio-conjugates. Conjugates were synthesized via carbodiimide chemistry and characterized by ¹H NMR and FTIR. Conjugation of DTX and GEM via linkers showed diverse physiochemical and plasma stability profile. Cellular uptake mechanism in MCF-7 and MDA-MB-231 cell lines revealed clathrin mediated internalization of bio-conjugates developed by using long length linkers, leading to higher cytotoxicity compared with free drug congeners. DTX-PEG3500-GEM and DTX-PEG2000-GEM demonstrated 4.21 and 3.81-fold higher AUC_(0-∞) of GEM in comparison with GEM alone. DTX-PEG2000-GEM and DTX-PEG3500-GEM exhibited reduced hepato-, nephro- and haemolytic toxicity as evident via histopathology, biochemical markers and SEM analysis of RBCs. Conclusively, PEG2000 and PEG3500 significantly improved pharmacokinetics without any sign of toxicity and hence can be explored further for the development of dual-drug conjugates for better therapeutic efficacy.
Co-delivery of docetaxel and gemcitabine using PEGylated self-assembled stealth nanoparticles for improved breast cancer therapy
2018, Nanomedicine: Nanotechnology, Biology, and Medicine
Citation Excerpt :
Further, 100 μl of plasma was precipitated by 200 μl of acetonitrile and then centrifuged at 10,000 rpm for 10 min at 4 °C. The supernatant was separated and analyzed for GEM content by validated HPLC method.20,21 The pharmacokinetic data was analysed by one compartmental model, using Kinetica software (Thermo scientific).
The present report deals with conjugation of dual drug; docetaxel (DTX) and gemcitabine (GEM) with linker poly-ethylene-glycol (PEG) to develop amphiphilic molecule having self-assembled property. The synthesized conjugate (DTX-PEG-GEM) demonstrated critical micelle concentration (CMC) in the range of 5–10 μg/ml which self-assembled to form NPs with size 124.2 ± 5.7. Remarkably higher coumarin-6 (C-6) fluorescence signals observed in case of C-6 loaded NPs, suggested enhanced cellular uptake via clathrin mediated endocytosis. Developed NPs demonstrated 4.8-fold higher AUC_(0-∞) value of GEM in comparison with Gemzar®. Tumor growth inhibition study demonstrated significant reduction in tumor volume and higher survival rate with NPs. Moreover, NPs demonstrated significantly lower hepato- and nephro-toxicity, evident from both histopathological sections and biochemical markers level estimation, and hemolytic toxicity. Data in hand suggest enhanced therapeutic efficacy and reduced toxicity of developed NPs over conventional drugs, resulting in efficient combinatorial chemotherapeutic-regimen and patient compliance, which is still an unmet task.
Individualizing Dosage Regimens of Antineoplastic Agents
2017, Individualized Drug Therapy for Patients: Basic Foundations, Relevant Software and Clinical Applications
There are still a number of limitations to the full use of therapeutic drug monitoring (TDM) to optimize chemotherapy in oncology. Probably the most important ones arise from the conservatism of clinical practice and the lack of training of physicians in pharmacokinetics (PK). Pharmacogenetics and biomarkers are being incorporated much faster, although the evidence for them is less at present, perhaps because of the lack of training of physicians in quantitative PK approaches rather than remembering clinical facts. Therapy with methotrexate, carboplatin, irinotecan, taxanes, busulfan, 5-fluorouracil, tyrosine kinase inhibitors, and other drugs can be optimized through TDM. In some cases, TDM is used mainly to control toxicity, but it is also useful sometimes to maximize efficacy. Anticancer therapy is best done in a comprehensive manner, incorporating approximate tools for each type and tumor stage. Surgery, radiotherapy, and chemotherapy each have their place. Achieving specific optimal therapeutic target goals for each patient can be feasible, as target ranges of serum drug concentrations are becoming rapidly available. This chapter summarizes the existing evidence concerning the use of TDM in the management of antineoplastic drug therapy.
Development of RP-HPLC method for simultaneous determination of docetaxel and curcumin in rat plasma: Validation and stability
2017, Asian Journal of Pharmaceutical Sciences
The purpose of the present research was to develop a suitable, simple, precise, accurate, robust, and reproducible RP-HPLC method for a reliable simultaneous quantification of docetaxel (DTX) and curcumin (CCM) in rat plasma samples using paclitaxel (PTX) as an internal standard. The samples were assayed by the Agilent 1260 Infinity HPLC instrument using a Capcell Pak C₈ column (4.6 mm × 150 mm, 5 µm) under isocratic conditions. The mobile phase consisted of acetonitrile and triple distilled water (40/60, v/v) with a flow rate of 1.0 ml/min. The eluent was monitored at 230 nm for simultaneous measurement of curcumin and docetaxel. The method was validated by determining system suitability, selectivity, sensitivity, linearity, inter-day and intra-day precision, accuracy, robustness, and stability in accordance with the guidelines of the United States Food and Drug Administration (FDA). The developed chromatographic method proved to be simple, precise, accurate, robust and reproducible. Moreover, the samples showed stability at room temperature over a period of 48 h. Thus, this method would be employed for routine simultaneous quantification of docetaxel and curcumin in rat plasma samples.
Simultaneous online SPE-HPLC-MS/MS analysis of docetaxel, Temsirolimus and sirolimus in whole blood and human plasma
2013, Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences
Citation Excerpt :
As Koal et al. described in their study [26], MRM detection mode in MS/MS system, allows simultaneous quantitative determination of antitumoral drugs with high specificity, low detection limits and very little time of analysis. These methods are much more sensitive than HPLC–UV methods although they have been widely used [4,12,14,17,24,25]. The aim of the current study was to develop a sensitive, fast and convenient method for the simultaneous identification and quantification of docetaxel, temsirolimus and its main metabolite, sirolimus, using paclitaxel as internal standard.
Docetaxel and temsirolimus are some of the most used drugs in a wide range of solid tumors. In preclinical studies, mTOR inhibitors such as temsirolimus have demonstrated synergistic cytotoxic effects with taxanes providing the rationale for combination studies. These anticancer agents exhibit a narrow therapeutic concentration range and due to their high inter- and intra-individual pharmacokinetic variability, therapeutic dose monitoring by highly sensitive methods as LC–MS/MS are important for clinical research. Therefore, the aim of this study was to develop and validate a sensitive, fast and convenient method for the simultaneous identification and quantification of docetaxel, temsirolimus and its main metabolite, sirolimus, using paclitaxel, another anticancer drug, as the internal standard. These analytes were quantified by an integrated online solid phase extraction–high performance liquid chromatography–tandem mass spectrometry (SPE–HPLC–MS/MS) system. Separation was performed on a Zorbax eclipse XDB-C8 (150 mm × 4.6 mm, 5 μm) column. The mass spectrometer tandem quadruple detector was equipped with jet stream electrospray ionization, monitored in multiple reactions monitoring (MRM) and operated in positive mode. A combination of protein precipitation with methanol/zinc sulphate (70:30) (v/v) and online SPE using a Zorbax eclipse plus C8 (12.5 mm × 4.6 mm, 5 μm) cartridge was used to extract the compounds. This method allows the use of the same reagents, sample treatment and analytical technique independently of whether the samples are whole blood or plasma. The method has been successfully validated and applied to real samples. It is a suitable method for dose adjustment and for evaluating potential drug interactions during combined treatments.
High-throughput plasma docetaxel quantification by liquid chromatography-tandem mass spectrometry
2011, Clinica Chimica Acta
The most valuable treatment option for breast, prostate and lung carcinomas is at present represented by a low dose of docetaxel, administered on a weekly basis. A better understanding of docetaxel pharmacokinetic and pharmacodynamic profiles could lead to an improvement in this dose regimen efficacy.
In this study a high-throughput method is described for the rapid quantification of docetaxel for large clinical pharmacology investigations. This analytical approach is based on an automatic on-line purification and enrichment technique followed by a measurement in tandem mass spectrometry through Multiple Reaction Monitoring.
The assay was validated over a 0.15–1500 ng/mL range. Intra-day precision ranged from 1.9% to 6.4%, while the inter-day was between 7.6% and 11.2%. The mean deviation from the nominal value ranged from − 0.5% to 5.6% for the intra-day, and from − 0.4% to 3.1% for the inter-day assay. Clinical applicability was demonstrated by measuring plasma pharmacokinetics in patients receiving weekly 25–35 mg/m² of docetaxel.
The proposed LC–MS/MS assay was found to have a better performance than previously reported methods in terms of sensitivity and sample preparation. It does not require any laborious pre-analytical manipulation and can be easily employed in large clinical pharmacology studies.

View all citing articles on Scopus

View full text

Short communicationDetermination of Taxotere in human plasma by a semi-automated high-performance liquid chromatographic method

Abstract

J. Pharm. Biomed. Anal.

J. Clin. Pharmacol.

J. Med. Chem.

Cancer Res.

Short communication
Determination of Taxotere in human plasma by a semi-automated high-performance liquid chromatographic method